Status:
COMPLETED
Immunomodulation Following Transfusion
Lead Sponsor:
University of Washington
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Bloodworks
Conditions:
Blood Component Transfusion
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study is designed to provide information on patients' immune response after exposure to transfused blood. Blood transfusions may have opposite immune effects on patients. One is sensitization. T...
Detailed Description
Blood transfusions may have opposite immune effects on patients. One is sensitization. The other is immunosuppression. The magnitude of this problem in patients who are not on chemotherapy is unknown....
Eligibility Criteria
Inclusion
- At least 18 year of age
- Scheduled for open heart surgery of cardiopulmonary bypass that involves: CABG, CABG with valve, aneurysm repair
- Urgent or elective surgery
Exclusion
- Scheduled for open heart surgery of cardiopulmonary bypass that involves: placement of a ventricular assist device, cardiac transplantation, aortic dissection repair
- Emergent surgery
- participation in other clinical research studies within 30 days of randomization.
- Immunosuppressive treatment.
- Refuse blood transfusion
- Disease or condition placing subject at undue risk or decision of attending doctor.
- Condition requiring high volume transfusion therapy
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
287 Patients enrolled
Trial Details
Trial ID
NCT00810810
Start Date
July 1 2006
End Date
August 1 2011
Last Update
December 26 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwest Hospital
Seattle, Washington, United States, 98133
2
University of Washington Medical Center
Seattle, Washington, United States, 98195